Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 3/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6797949 | 0.89 | PTGES (0.39) | PTGESCCNA2CDK2CCNA1NAMPT | |
| SCHEMBL6792946 | 0.89 | CCNA2 (0.37) | PTGESCCNA2CDK2CCNA1NAMPT | |
| SCHEMBL6799128 | 0.88 | NAMPT (0.39) | CCNA2CDK2CCNA1NAMPT | |
| SCHEMBL4262524 | 0.86 | ROCK2 (0.33) | — | |
| SCHEMBL6792445 | 0.86 | — | — | |
| SCHEMBL6795498 | 0.84 | ROCK2 (0.32) | — | |
| SCHEMBL6788882 | 0.84 | — | — | |
| SCHEMBL6787713 | 0.84 | L3MBTL1 (0.36) | CCNA2CDK2CCNA1 | |
| SCHEMBL6793383 | 0.83 | SLC6A9 (0.34) | — | |
| SCHEMBL6793127 | 0.82 | ALDH1A1 (0.39) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | PTGES 1542/4885CCNA2 270/4885CDK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.